Clinical Trial Update: A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase II study of nivolumab plus cabozantinib for metastatic triple-negative breast cancer has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• cabozantinib (cabozantinib)
• nivolumab (nivolumab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2021-12-28